Abbott Laboratories vs Johnson & Johnson — Stock Comparison
Abbott Laboratories (ABT) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson narrowly edges Abbott Laboratories on Q·Score (7 vs 6.4 out of 10), primarily on Quality (9.3 vs 5.2). Abbott Laboratories scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst consensus targets imply greater upside for ABT (+9.6%) than for JNJ (+1.9%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
74% of 27 covering analysts have a positive rating.
⚠ weak profitability metrics drag quality score.
High-quality business with 26% return on equity and 21% profit margins.
⚠ earnings contracting 1% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
ABT vs JNJ: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7/10 versus Abbott Laboratories (ABT) at 6.4/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: ABT or JNJ?
Abbott Laboratories (ABT) scores higher on Growth (5.5/10 vs 5/10). Abbott Laboratories reports revenue growth (13.0% YoY) while Johnson & Johnson reports (6.6% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is ABT or JNJ more attractively valued?
Abbott Laboratories (ABT) scores higher on Valuation (7.5/10 vs 6.5/10). ABT trades at 17.8× P/E versus JNJ at 20.7×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about ABT vs JNJ?
There are 24 analysts covering ABT with a consensus price target of $118.42, and 22 analysts covering JNJ with a consensus target of $270.59. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: ABT or JNJ?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 5.2/10). Net profit margin: ABT at 11.6%, JNJ at 21.5%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: ABT or JNJ?
Abbott Laboratories (ABT) scores higher on Financial Health (7/10 vs 6.5/10). Market beta: ABT at 0.61, JNJ at 0.23. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of ABT and JNJ?
Abbott Laboratories (ABT) has a market capitalisation of $186.9B, while Johnson & Johnson (JNJ) has a market cap of $639.9B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do ABT or JNJ pay dividends?
ABT pays a dividend yield of 2.35%, while JNJ pays a dividend yield of 2.01%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →